{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:58:15Z","timestamp":1791374295070,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.xphs.2016.03.033","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T07:01:14Z","timestamp":1464246074000},"page":"1995-2004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Linking Suspension Nasal Spray Drug Deposition Patterns to\u00a0Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics"],"prefix":"10.1016","volume":"105","author":[{"given":"Alex","family":"Rygg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Worth","family":"Longest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xphs.2016.03.033_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1M141","article-title":"Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration","volume":"43","author":"Davit","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.xphs.2016.03.033_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1208\/s12248-013-9494-2","article-title":"Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval","volume":"15","author":"Li","year":"2013","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.xphs.2016.03.033_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/jam.2006.19.510","article-title":"Validity of in\u00a0vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response","volume":"19","author":"Suman","year":"2006","journal-title":"J\u00a0Aerosol Med"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/s12248-010-9242-9","article-title":"Scientific considerations for generic synthetic salmon calcitonin nasal spray products","volume":"13","author":"Lee","year":"2011","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.xphs.2016.03.033_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/009127000004001107","article-title":"Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers","volume":"40","author":"Affrime","year":"2000","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2016.03.033_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00228-004-0763-y","article-title":"Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays","volume":"60","author":"Daley-Yates","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.2012.04222.x","article-title":"Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray","volume":"74","author":"Derendorf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2016.03.033_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.0306-5251.2001.01374.x","article-title":"Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man","volume":"51","author":"Daley-Yates","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2016.03.033_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00613465","article-title":"Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man","volume":"29","author":"Edsb\u00e4cker","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2165\/00044011-199714010-00006","article-title":"Pharmacokinetics and bioavailability of intranasal fluticasone in humans","volume":"14","author":"McDowall","year":"1997","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2500\/aap.2015.36.3817","article-title":"Regional deposition of mometasone furoate nasal spray suspension in humans","volume":"36","author":"Shah","year":"2015","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib12","first-page":"121","article-title":"Towards clinically relevant in\u00a0vitro testing of locally acting nasal spray suspension products","volume":"12","author":"Azimi","year":"2015","journal-title":"Respiratory Drug Delivery Europe"},{"issue":"5","key":"10.1016\/j.xphs.2016.03.033_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/08958370151126185","article-title":"Use of computational fluid dynamics models for dosimetry of inhaled gases in the nasal passages","volume":"13","author":"Kimbell","year":"2001","journal-title":"Inhal Toxicol"},{"issue":"3","key":"10.1016\/j.xphs.2016.03.033_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/08958370500434172","article-title":"Transport and uptake of MTBE and ethanol vapors in a human upper airway model","volume":"18","author":"Zhang","year":"2006","journal-title":"Inhal Toxicol"},{"issue":"5","key":"10.1016\/j.xphs.2016.03.033_bib15","doi-asserted-by":"crossref","first-page":"051003","DOI":"10.1115\/1.4001045","article-title":"Development of a CFD boundary condition to model transient vapor absorption in the respiratory airways","volume":"132","author":"Tian","year":"2010","journal-title":"J\u00a0Biomech Eng"},{"issue":"2","key":"10.1016\/j.xphs.2016.03.033_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10439-009-9808-9","article-title":"Transient absorption of inhaled vapors into a multilayer mucus-tissue-blood system","volume":"38","author":"Tian","year":"2010","journal-title":"Ann Biomed Eng"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/taap.1998.8407","article-title":"A\u00a0CFD PBPK hybrid model for simulating gas and vapor uptake in the rat nose","volume":"150","author":"Bush","year":"1998","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.xphs.2016.03.033_bib18","doi-asserted-by":"crossref","DOI":"10.1089\/jamp.2015.1252","article-title":"Absorption and clearance of pharmaceutical aerosols in the human nose: development of a CFD model","author":"Rygg","year":"2016","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2016.03.033_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11095-015-1837-5","article-title":"Absorption and clearance of pharmaceutical aerosols in the human nose: effects of nasal spray suspension particle size and properties","volume":"33","author":"Rygg","year":"2016","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2016.03.033_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaerosci.2010.12.004","article-title":"Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child","volume":"42","author":"Xi","year":"2011","journal-title":"J\u00a0Aerosol Sci"},{"issue":"23-24","key":"10.1016\/j.xphs.2016.03.033_bib21","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1016\/j.ijheatmasstransfer.2008.04.037","article-title":"Numerical predictions of submicrometer aerosol deposition in the nasal cavity using a novel drift flux approach","volume":"51","author":"Xi","year":"2008","journal-title":"Int J Heat Mass Tran"},{"issue":"2","key":"10.1016\/j.xphs.2016.03.033_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0021-8502(73)90063-3","article-title":"Regional deposition and clearance of particles in the human nose","volume":"4","author":"Fry","year":"1973","journal-title":"J\u00a0Aerosol Sci"},{"issue":"1-3","key":"10.1016\/j.xphs.2016.03.033_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J\u00a0Control Release"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.03.033_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int J Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2016.03.033_bib25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2016.03.033_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.addr.2008.09.006","article-title":"Mathematical modeling of molecular diffusion through mucus","volume":"61","author":"Cu","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2016.03.033_bib27","series-title":"Introduction to Chemical Transport in the Environment","author":"Gulliver","year":"2007"},{"key":"10.1016\/j.xphs.2016.03.033_bib28","unstructured":"Merck Nasonex Product Monograph. Available at: http:\/\/www.merck.ca\/assets\/en\/pdf\/products\/NASONEX-PM_E.pdf. Accessed August 15, 2015."},{"issue":"4","key":"10.1016\/j.xphs.2016.03.033_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2133\/dmpk.22.225","article-title":"Solubility and dissolution profile assessment in drug discovery","volume":"22","author":"Sugano","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.xphs.2016.03.033_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s11095-010-0070-5","article-title":"In\u00a0vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products","volume":"27","author":"Arora","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2016.03.033_bib31","first-page":"9","article-title":"Physiology and pathophysiology of the paranasal sinuses","volume":"9","author":"Beule","year":"2010","journal-title":"GMS Curr Top Otorhinolaryngol Head Neck Surg"},{"issue":"7","key":"10.1016\/j.xphs.2016.03.033_bib32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1015830907632","article-title":"The nasal mucociliary clearance: relevance to nasal drug delivery","volume":"8","author":"Schipper","year":"1991","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2016.03.033_bib33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J\u00a0Pharm Pharm Sci"},{"key":"10.1016\/j.xphs.2016.03.033_bib34","unstructured":"FDA Nasonex Product Information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/20762s11lbl.pdf. Accessed August 15, 2015."},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1208\/s12248-012-9420-z","article-title":"A\u00a0pharmacokinetic simulation tool for inhaled corticosteroids","volume":"15","author":"Weber","year":"2013","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(97)00068-9","article-title":"Mathematical modeling of deposition and disposition of drugs administered via the nose","volume":"29","author":"Gonda","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1015891727080","article-title":"Model of disposition of drugs administered into the human nasal cavity","volume":"7","author":"Gonda","year":"1990","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2016.03.033_bib38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jps.20049","article-title":"Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate","volume":"93","author":"Valotis","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 3","key":"10.1016\/j.xphs.2016.03.033_bib40","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.xphs.2016.03.033_bib41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/jam.2006.19.92","article-title":"Nasal clearance in health and disease","volume":"19","author":"Illum","year":"2006","journal-title":"J\u00a0Aerosol Med"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916413365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916413365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T16:44:35Z","timestamp":1692377075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916413365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0022354916413365"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.03.033","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linking Suspension Nasal Spray Drug Deposition Patterns to\u00a0Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}